Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril

<b>Background/Objectives</b>: Since 2023, enalapril orodispersible minitablets have been approved in Europe for paediatric heart failure from birth, but no population pharmacodynamic analyses have yet been conducted in this patient group. The objectives were to investigate the effect of the active m...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Melina Steichert, Willi Cawello, Bjoern B. Burckhardt, Fabian K. Suessenbach, Stephanie Laeer, on behalf of the LENA Consortium
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2025-10-01
סדרה:	Pharmaceutics
נושאים:	enalapril pharmacokinetic/pharmacodynamic model angiotensin-converting enzyme inhibitor angiotensin II/angiotensin I ratio paediatric heart failure
גישה מקוונת:	https://www.mdpi.com/1999-4923/17/10/1345
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!